vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and PLUMAS BANCORP (PLBC). Click either name above to swap in a different company.

PLUMAS BANCORP is the larger business by last-quarter revenue ($28.6M vs $20.6M, roughly 1.4× Pulmonx Corp). On growth, PLUMAS BANCORP posted the faster year-over-year revenue change (35.1% vs -8.7%). Over the past eight quarters, PLUMAS BANCORP's revenue compounded faster (20.8% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Plumas Bancorp is a U.S.-based bank holding company operating through its subsidiary Plumas Bank. It provides full-spectrum retail and commercial banking services including deposit products, consumer and commercial loans, small business financing, and wealth management for individual customers, SMEs and local community groups across northern California and Nevada.

LUNG vs PLBC — Head-to-Head

Bigger by revenue
PLBC
PLBC
1.4× larger
PLBC
$28.6M
$20.6M
LUNG
Growing faster (revenue YoY)
PLBC
PLBC
+43.7% gap
PLBC
35.1%
-8.7%
LUNG
Faster 2-yr revenue CAGR
PLBC
PLBC
Annualised
PLBC
20.8%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
PLBC
PLBC
Revenue
$20.6M
$28.6M
Net Profit
$-13.7M
Gross Margin
77.9%
Operating Margin
-40.9%
48.9%
Net Margin
-66.3%
Revenue YoY
-8.7%
35.1%
Net Profit YoY
5.5%
EPS (diluted)
$-0.33
$1.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
PLBC
PLBC
Q1 26
$20.6M
Q4 25
$22.6M
$28.6M
Q3 25
$21.5M
$27.4M
Q2 25
$23.9M
$20.5M
Q1 25
$22.5M
$21.8M
Q4 24
$23.8M
$21.2M
Q3 24
$20.4M
$21.1M
Q2 24
$20.8M
$20.6M
Net Profit
LUNG
LUNG
PLBC
PLBC
Q1 26
$-13.7M
Q4 25
$-10.4M
Q3 25
$-14.0M
$5.1M
Q2 25
$-15.2M
$6.3M
Q1 25
$-14.4M
$7.2M
Q4 24
$-13.2M
Q3 24
$-14.1M
$7.8M
Q2 24
$-15.3M
$6.8M
Gross Margin
LUNG
LUNG
PLBC
PLBC
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
PLBC
PLBC
Q1 26
-40.9%
Q4 25
-43.8%
48.9%
Q3 25
-66.9%
25.2%
Q2 25
-62.0%
42.2%
Q1 25
-64.6%
46.1%
Q4 24
-56.5%
50.3%
Q3 24
-69.3%
50.6%
Q2 24
-75.2%
45.1%
Net Margin
LUNG
LUNG
PLBC
PLBC
Q1 26
-66.3%
Q4 25
-46.1%
Q3 25
-64.9%
18.8%
Q2 25
-63.6%
30.8%
Q1 25
-64.1%
33.0%
Q4 24
-55.4%
Q3 24
-69.4%
37.1%
Q2 24
-73.7%
32.9%
EPS (diluted)
LUNG
LUNG
PLBC
PLBC
Q1 26
$-0.33
Q4 25
$-0.25
$1.56
Q3 25
$-0.34
$0.73
Q2 25
$-0.38
$1.05
Q1 25
$-0.36
$1.20
Q4 24
$-0.33
$1.30
Q3 24
$-0.36
$1.31
Q2 24
$-0.39
$1.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
PLBC
PLBC
Cash + ST InvestmentsLiquidity on hand
$61.6M
$80.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$45.8M
$261.1M
Total Assets
$120.0M
$2.2B
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
PLBC
PLBC
Q1 26
$61.6M
Q4 25
$69.8M
$80.6M
Q3 25
$76.5M
$87.3M
Q2 25
$75.5M
$79.3M
Q1 25
$74.6M
$87.3M
Q4 24
$70.9M
$82.0M
Q3 24
$63.3M
$118.0M
Q2 24
$63.5M
$109.9M
Total Debt
LUNG
LUNG
PLBC
PLBC
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
LUNG
LUNG
PLBC
PLBC
Q1 26
$45.8M
Q4 25
$54.1M
$261.1M
Q3 25
$60.0M
$245.9M
Q2 25
$69.1M
$193.1M
Q1 25
$77.7M
$187.6M
Q4 24
$85.8M
$177.9M
Q3 24
$93.9M
$181.9M
Q2 24
$101.2M
$165.2M
Total Assets
LUNG
LUNG
PLBC
PLBC
Q1 26
$120.0M
Q4 25
$129.3M
$2.2B
Q3 25
$138.3M
$2.2B
Q2 25
$147.2M
$1.6B
Q1 25
$150.7M
$1.6B
Q4 24
$162.8M
$1.6B
Q3 24
$167.4M
$1.7B
Q2 24
$172.6M
$1.6B
Debt / Equity
LUNG
LUNG
PLBC
PLBC
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
PLBC
PLBC
Operating Cash FlowLast quarter
$21.6M
Free Cash FlowOCF − Capex
$20.3M
FCF MarginFCF / Revenue
70.9%
Capex IntensityCapex / Revenue
4.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$34.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
PLBC
PLBC
Q1 26
Q4 25
$-7.1M
$21.6M
Q3 25
$-8.2M
$5.6M
Q2 25
$-3.9M
$2.1M
Q1 25
$-13.2M
$7.5M
Q4 24
$-6.7M
$30.5M
Q3 24
$-7.2M
$8.0M
Q2 24
$-5.8M
$5.1M
Free Cash Flow
LUNG
LUNG
PLBC
PLBC
Q1 26
Q4 25
$-7.1M
$20.3M
Q3 25
$-8.3M
$4.8M
Q2 25
$-4.0M
$2.0M
Q1 25
$-13.5M
$7.3M
Q4 24
$-6.8M
$29.8M
Q3 24
$-7.7M
$7.8M
Q2 24
$-6.2M
$4.8M
FCF Margin
LUNG
LUNG
PLBC
PLBC
Q1 26
Q4 25
-31.4%
70.9%
Q3 25
-38.4%
17.5%
Q2 25
-16.6%
9.9%
Q1 25
-60.0%
33.7%
Q4 24
-28.8%
141.0%
Q3 24
-37.6%
37.1%
Q2 24
-30.0%
23.5%
Capex Intensity
LUNG
LUNG
PLBC
PLBC
Q1 26
Q4 25
0.1%
4.6%
Q3 25
0.4%
2.9%
Q2 25
0.2%
0.2%
Q1 25
1.3%
0.8%
Q4 24
0.5%
3.2%
Q3 24
2.0%
0.7%
Q2 24
2.3%
1.1%
Cash Conversion
LUNG
LUNG
PLBC
PLBC
Q1 26
Q4 25
Q3 25
1.09×
Q2 25
0.33×
Q1 25
1.04×
Q4 24
Q3 24
1.02×
Q2 24
0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons